- Record: found
- Abstract: found
- Article: not found
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Srdan Verstovsek
1 ,
Ruben A Mesa ,
Jason Gotlib ,
Richard S Levy ,
Vikas Gupta ,
John F DiPersio ,
John V Catalano ,
Michael Deininger ,
Carole Miller ,
Richard T Silver ,
Moshe Talpaz ,
Elliott F Winton ,
Jimmie H Harvey ,
Murat O Arcasoy ,
Elizabeth Hexner ,
Roger M Lyons ,
Ronald Paquette ,
Azra Raza ,
Kris Vaddi ,
Susan Erickson-Viitanen ,
Iphigenia L Koumenis ,
William Sun ,
Victor Sandor ,
Hagop M Kantarjian
Mar 01 2012
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis.